Front. Chem. Frontiers in Chemistry Front. Chem. 2296-2646 Frontiers Media S.A. 1082236 10.3389/fchem.2022.1082236 Chemistry Correction Corrigendum: Dual-specificity phosphatase CDC25B was inhibited by natural product HB-21 through covalently binding to the active site Zhang et al. 10.3389/fchem.2022.1082236 Zhang Shoude 1 2 * Jia Qiangqiang 1 Gao Qiang 1 Fan Xueru 2 Weng Yuxin 2 Su Zhanhai 1 2 * 1 State Key Laboratory of Plateau Ecology and Agriculture, Qinghai University, Xining, China 2 Department of Pharmacy, Medical College of Qinghai University, Xining, China

Edited and reviewed by: Michael Kassiou, The University of Sydney, Australia

 *Correspondence: Shoude Zhang, shoude.zhang@qhu.edu.cn; Zhanhai Su, suzhanhai@foxmail.com

This article was submitted to Medicinal and Pharmaceutical Chemistry, a section of the journal Frontiers in Chemistry

 18 11 2022 2022 10 1082236 31 10 2022 10 11 2022 Copyright © 2022 Zhang, Jia, Gao, Fan, Weng and Su. 2022 Zhang, Jia, Gao, Fan, Weng and Su

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Dual-specificity phosphatase CDC25B was inhibited by natural product HB-21 through covalently binding to the active site by Zhang S, Jia Q, Gao Q, Fan X, Weng Y and Su Z (2018). Front. Chem. 6:531. doi: 10.3389/fchem.2018.00531 Cdc25B inhibitor sesquiterpene lactone anticancer cell cycle progression covalent binding to protein

In the original article, there was an error in the affiliations as published, in which a third affiliation was wrongly included for author “Shoude Zhang”. The correct affiliations appear above.

In the original article, there was an error in Figure 6, page 4, as published. In the same batch of experiments, WB experiments for two compounds were done at the same time, and the article incorrectly used the results of another drug in the experiments. The corrected Figure 6 and its caption appear below.

Inhibition of CDK1 dephosphorylation caused by HB-21. The cells in the G2/M phase were treated with the indicated concentration of HB-21 or DMSO for 4 h, and then harvested. The samples were processed for Western blot analysis.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.